# PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours

Source: https://onco.cc/key-papers/paper-promid-rinke-jco-2009/  
OnCo record `paper-promid-rinke-jco-2009` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The PROMID trial was the first to show that a somatostatin analogue, octreotide, slows tumour growth in midgut neuroendocrine tumours, more than doubling the time to progression compared with placebo.

## Summary

Phase 3 placebo-controlled trial of 85 treatment-naive patients with well-differentiated metastatic midgut neuroendocrine tumours randomised to octreotide LAR 30 mg monthly or placebo.

Median time to tumour progression was 14.3 versus 6.0 months (hazard ratio 0.34), with the greatest benefit in patients with low hepatic tumour load and resected primary tumours.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2009
- DOI: 10.1200/JCO.2009.22.8510
- Authors: Rinke A, Müller HH, Schade-Brittinger C, et al.
- Findings: Median time to progression 14.3 vs 6.0 months; hazard ratio 0.34.; Benefit largest with hepatic tumour load of 10 percent or less.
- What it means: Octreotide LAR became a standard first-line antiproliferative therapy for small intestinal neuroendocrine tumours, later joined by lanreotide after CLARINET.
- Caveats: Small trial that closed early for slow accrual.; No overall survival benefit because of crossover.

## Sources

- J Clin Oncol 2009: https://doi.org/10.1200/JCO.2009.22.8510
- PubMed: https://pubmed.ncbi.nlm.nih.gov/19704057/

## Connected records

- cancers: [Small intestinal neuroendocrine tumours](https://onco.cc/cancers/small-intestinal-net/)
- trials: [PROMID](https://onco.cc/trials/promid/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-promid-rinke-jco-2009.json